Safety and Dose Finding Study of Oral MP470, a Multi-Targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens.

Trial Profile

Safety and Dose Finding Study of Oral MP470, a Multi-Targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs Amuvatinib; Carboplatin; Docetaxel; Erlotinib; Etoposide; Paclitaxel; Topotecan
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 19 Jan 2011 Actual end date (December 2009) added as reported by ClinicalTrials.gov.
    • 19 Jan 2011 Actual end date (December 2009) added as reported by ClinicalTrials.gov.
    • 19 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top